SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

ARMP

Armata Pharmaceuticals, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed4d 7h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The Phase 3 start timing for AP-SA02 is the key catalyst; monitor FDA protocol concurrence and any further non-dilutive funding announcements. The convertible loan fair value gain is non-recurring and does not reflect operational improvement.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

ARMP drug pipeline →

AP-SA02

◆ Mixed Named in this press release
Impact
Phase
Phase 2 complete; Phase 3 (registrational) planned for H2 2026
Time to market
Phase 3 (registrational) initiation expected H2 2026; pivotal data and any BLA/approval are realistically 2028-2030 at the earliest, contingent on Phase 3 success — AP-SA02 is years from commercialization.
Next catalyst
None dated

What to watchWatch for confirmation of the Phase 3 start (H2 2026 window) and any financing announcement, because the ~$5.07 stock's biggest near-term risks are cash runway and dilution, not trial mechanics. The real share-price binary, Phase 3 topline data, is likely 2+ years out, so treat the gap between the stock and the ~$17.5 mean analyst target as a long-dated optionality play, not a near-term event.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$3.87
T+0 close · Nov 12, 2026 · via day close
Latest settled
−22.74%
T+1 · $2.99
Vs SPY
−20.83%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $3.87entry
  2. T+1 · 17h ago −22.74%α −20.83% · $2.99
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Armata Pharmaceuticals reported Q3 2026 GAAP net income of $54.9M ($1.15 basic EPS, $(0.24) diluted EPS), driven by a $69.6M non-cash gain from convertible loan fair value change. Operating loss narrowed to $7.4M from $7.8M a year ago. The company is preparing for a Phase 3 study of AP-SA02, which received FDA Breakthrough Therapy designation, and received $3.7M in non-dilutive DoW funding. Consensus EPS of $(0.56) was not met on a GAAP basis; the diluted loss per share of $(0.24) compares to a consensus estimate of $(0.56), representing a beat of 57.1%.

Key Financial Metrics

EPS
−$0.24
est −$0.56 · +57.1%
Revenue
$3.2M
est $450.0K · +604.7% · +173.6% YoY
Rating
beat
Free Cash Flow
-$20.1M

Key Facts

  • Q3 2026 net income $54.9M vs net loss $(26.7M) in Q3 2025, driven by $69.6M gain from convertible loan fair value change
  • Diluted EPS $(0.24) vs consensus $(0.56), beat of 57.1%
  • Operating loss improved to $7.4M from $7.8M in Q3 2025
  • Grant and award revenue $3.2M, up from $1.2M in Q3 2025
  • Cash and equivalents $18.3M as of Sep 30, 2026, up from $8.7M at Dec 31, 2025
  • Received FDA Breakthrough Therapy designation for AP-SA02
  • Received $3.7M in non-dilutive DoW funding for Phase 3 preparation
  • Phase 3 study of AP-SA02 expected to initiate in H2 2026, pending FDA protocol concurrence
  • Two new U.S. patents issued for AP-SA02 and AP-PA02

Financial Impact

Net income of $54.9M primarily from non-cash fair value gain; operating cash burn of $(20.0M) in 9M 2026; cash position $18.3M

net incomeepscashoperating loss

Risk Factors

  • Net income driven by non-cash fair value gain, not operational profitability
  • Cash burn continues with $20.0M used in operations over 9 months; $18.3M cash may require additional financing before Phase 3 completion
  • Phase 3 initiation dependent on FDA protocol agreement, timeline uncertain
  • Diluted share count of 62.7M reflects convertible loan dilution

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302938272

Track record

6 reports on ARMP

Performance horizon

1 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +43.90% at T+60 after the May 13, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 5/10 Viewing Entry $3.87 Now $2.99 −22.74% settles Dec 14
  2. Sep 23, 20267w ago 8-K Bullish 5/10 Entry $3.64 to $3.06 Now $2.99 −17.86% ▼ −15.93% −16.62% vs SPY
  3. Sep 14, 20269w ago 8-K Bullish 7/10 Entry $5.55 to $3.63 Now $2.99 −46.13% ▼ −34.59% −36.86% vs SPY
  4. Jul 20, 202617w ago 8-K Bullish 5/10 Entry $5.06 to $4.48 Now $2.99 −40.91% ▼ −11.46% −15.58% vs SPY
  5. May 13, 202626w ago 8-K Bearish 6/10 Entry $8.20 to $7.58 Now $2.99 +63.54% ▲ +7.56% +6.70% vs SPY
  6. Apr 27, 202629w ago 8-K Neutral 3/10 Entry $11.00 to $8.17 Now $2.99 −72.82% ▼ −25.73% −30.68% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens Wed (9h 39m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026